Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 8/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17929531 | 0.85 | PDK2 (0.36) | PDK2KDM4ELMNAMAPT | |
| SCHEMBL17933198 | 0.84 | CHRM1 (0.36) | PDK2CHRM1HTR1AHTR1DHTR1B | |
| SCHEMBL17929534 | 0.83 | PDK2 (0.33) | PDK2LMNA | |
| SCHEMBL17929502 | 0.83 | PDK2 (0.34) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL17929533 | 0.82 | PDK2 (0.34) | PDK2LMNA | |
| SCHEMBL17929535 | 0.81 | PDK2 (0.33) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL17929497 | 0.79 | PDK2 (0.36) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL17929532 | 0.79 | PDK2 (0.33) | PDK2 | |
| SCHEMBL17929518 | 0.78 | PDK2 (0.34) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL20173123 | 0.77 | PDK2 (0.37) | PDK2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160211456-A1 | PHENANTHRO[9,10-b]TETRAPHENYLENE DERIVATIVE AND USE THEREOF | LUMINESCENCE TECHNOLOGY CORP. | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160211456-A1 | PHENANTHRO[9,10-b]TETRAPHENYLENE DERIVATIVE AND USE THEREOF | POP1, TERB1, AP2B1 | PDK2 2688/4885CHRM1 1504/4885HTR1A 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.